pharma news today obesity drugs glp-1 september 2025 Drugmakers are racing to find the next Wegovy. These trials are ones to watch ADA '26: Lilly's dominance, Pfizer's
Description
GI AEs arise irrespective of the half-life (long/short action) or route of administration (subcutaneous/oral) of the chosen GLP-1 RA
Exendin-4 B
Metabolic syndrome among patients with polycystic ovarian syndrome presenting to a tertiary care hospital: a descriptive cross-sectional study
Combining semaglutide and Ozempic is not safe or effective, as they are the same medication
In other words, prescribing medication to endangered animals
GLP-1 therapy is administered via subcutaneous injection once a week
